^
Association details:
| Biomarker: | VTCN1 underexpression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | felmetatug vedotin (PF-08046048) (Microtubule inhibitor, B7-H4-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
854 SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models
Published date:
11/09/2021
Excerpt:
Immunohistochemistry confirmed expression of B7-H4 across multiple solid tumor types, including ovarian and breast tumors….In vivo, SGN-B7H4V demonstrated strong anti-tumor activity in multiple xenograft models, including ovarian and breast cancer models.
DOI:
http://dx.doi.org/10.1136/jitc-2021-SITC2021.854
